万邦德WP203A获得美国孤儿药认定

Core Viewpoint - Wanbangde's subsidiary has received orphan drug designation from the FDA for WP203A (alfanorelin) to treat pemphigus [2] Group 1: Company Announcement - Wanbangde announced that its wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd., has received a recognition letter from the FDA [2] - The orphan drug designation is specifically for WP203A (alfanorelin), which is a synthetic agonist of the melanocortin-1 receptor (MC1R) [2] - Alfanorelin exerts its anti-inflammatory and immunomodulatory effects by activating the MC1R receptor [2] Group 2: Current Applications - Alfanorelin has already been successfully applied in the treatment of erythropoietic protoporphyria (EPP) [2]